Skip directly to page options Skip directly to A-Z link

Volume 1, Number 3—July 1995

Synopsis

Streptococcal Toxic-Shock Syndrome: Spectrum of Disease, Pathogenesis, and New Concepts in Treatment

Dennis L. Stevens
Author affiliation: Professor of Medicine, University of Washington School of Medicine, Seattle,Washington
Chief, Infectious Disease Section, Veterans Affairs Medical Center, Boise, Idaho, USA

Main Article

Figure

Pathogenesis of scarlet fever, bacteremia, and toxic shock syndrome. M-1+SPEA+=aGAS strain that contains M protein type 1 and streptococcal pyrogenic exotoxin A (SPEA); + anti-M-1 = the presence of antibody to M protein type 1; -anti-M-1 = the absence of antibody to M protein type 1;anti-SPEA+=antibody to SPEA; and DIC = disseminated intravascular coagulation.

Figure. Pathogenesis of scarlet fever, bacteremia, and toxic shock syndrome. M-1+SPEA+=aGAS strain that contains M protein type 1 and streptococcal pyrogenic exotoxin A (SPEA); + anti-M-1 = the presence of antibody to M protein type 1; -anti-M-1 = the absence of antibody to M protein type 1;anti-SPEA+=antibody to SPEA; and DIC = disseminated intravascular coagulation.

Download

Main Article

Page created: December 20, 2010
Page updated: December 20, 2010
Page reviewed: December 20, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external